CLINICAL STUDY  PROTOCOL  
 
 
 
 
Buprenorphine extended -release in  jail 
and at re -entry: pilot  proof -of-concept  
open -label  randomized  controlled trial 
vs. daily  sublingual  buprenorphine -
naloxone  
Clinical  Phase  
Phase  IV 
 
 
Sponsor  
National Institute on Drug  Abuse  
Protocol  Version  
December 11 , 2019  
version  10 
 
 
 
Study Number:  18-00823  
NCT:  [STUDY_ID_REMOVED]  
 
Confidentiality  Statement:  
This study will be conducted in accordance with the Code of Federal Regulations on  the 
Protection of Human Subjects (45 CFR Part 46), any other applicable US  government  
research regulations, and institutional research policies and procedures. The  Principal  
Investigator will assure that no deviation from, or changes to the protocol will take  place  
without  prior agreement  from the sponsor  and documented  approval  from the Institutional  
Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to  the 
trial participants.  All personnel  involved  in the conduct  of this study  have  completed  Human  
Subjects Protection  Training.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
2  
  
 
Study  Personnel  
Principal  Investigator  Joshua D  Lee 
New York  University  
Email:  Joshua.Lee@nyulangone.org  
 
 
Co-Investigators  Jonathan Giftos,  MD 
NYC  Health+Hospitals  
Email:  giftosj@nychhc.org  
 
Ross MacDonald,  MD 
NYC  Health+Hospitals  
Email:  rmacdonald@nychhc.org  
 
Key Study  Personnel:  Ryan  Mcdonald 
New York  University  
Email:  Ryan.Mcdonald@nyulangone.org  
 
Monica  Malone 
New York  University  
Email:  Mia.Malone@nyulangone.org  
 
Nadina  Santana -Correa  
New York  University  
Email:  Nadina.Santana -Correa@nyulangone.org  
Wanda Bonilla  
New York  University  
Email:  Wanda.Bonilla@nyulangone.org  
 
 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
3  
 Synopsis  
 
Primary  Objective  
Feasibility  and Implementation:  Estimate  the feasibility  and ease  of use of XRB vs. SLB 
as measured by initial patient preference and acceptability, in -treatment  patient  
satisfaction, patient qualitative interviews, jail visit frequency and program cost 
estimates, and rates of  medication diversion.  
Secondary  Objectives  
Treatment  Retention:  Estimate  the effectiveness  of XRB vs. SLB in improving  rates  of 
community treatment initiation/continuation  post-release.  
Clinical  Effectiveness:  Estimate  the effectiveness  of XRB vs. SLB in decreasing  illicit 
opioid (e.g. heroin) use  post-release.  
Naturalistic  Comparative  Effectiveness:  Evaluate  outcomes  of XRB vs. SLB in the context 
of the XRNTX, ETAU, and Methadone outcomes accrued in the larger  SOMATICS -XOR  
RCT.  
Primary Outcome  Variables  
1. Initial  patient  preference  and acceptability  measured  via baseline,  initial  patient  
interviews  
2. In-treatment patient satisfaction measured using follow -up surveys, qualitative 
interviewing, and  clinical research  forms  
3. Jail visit frequency and program cost  estimates  
4. Rates of medication  diversion.  
Secondary and Exploratory Outcome  Variables  
1. XRB vs. SLB in improving  rates  of community  treatment  initiation/continuation  post- 
release.  
2. Estimate  the effectiveness  of XRB vs. SLB in decreasing  illicit opioid  (e.g. heroin)  use 
post-release.  
3. Evaluate outcomes of XRB vs. SLB in the context of the XRNTX, ETAU,  and 
Methadone outcomes accrued in the larger SOMATICS -XOR  RCT 
Study  Duration  
June 28, 2019 — June 27,  2020  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
4  
  
 
Study  Design  
This Administrative  Supplement  proposal  takes  advantage  of the existing  SOMATICS - 
XOR  U01 (NIDA)  trial design  and infrastructure  to conduct  a new pilot,  N=50,  proof -of- 
concept, open -label, non -blinded randomized controlled trial of XRB vs.  SLB.  
Study  Population  
Adult jail inmates with upcoming release date, current opioid dependence and  currently 
maintained on subli ngual buprenorphine -naloxone.  N=50.  
Number of  Participants  
N=50  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
5  
  
 
Study  Flowchart  
 
Prior  to  
Enrollment  
Visit 0 
Screening  
 
 
Visit 0 
Baseline  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Visit 1-4 
Follow -Up 
Treatment  
 
 
Visit 5 
Final  Study  
Visit  
     
 
 
 
 
    Visit 6-10 
Extension  
Study  
Treatment 
Visits  
 
 
    Visit 11 
Extension 
Study  Final 
Visit  
 N: 50 
and HIPAA   potentia l  inclusion and  
exclusio n   medica l  document informed consen t and of 
eligibilit y in   
 Treatmen t Visits  
Administrativ e for SLB medicatio n refills and post-release XRB injections, Timeline  
 specime n collectio n  testing , adverse  event and seriou s adverse even  NYS 
 monitorin g data for  SLB refill ended -interview ,  
         
Perfor m Baselin e Assessments  
Timelin e   MOUD Preference Form,  Medica l 
 medica l and   
 
Buprenorphine  
Extended -Release  
Sublingual  
Buprenorphine  
Final Stud y Visit  
Medicatio n is not dispensed. Timelin e Followbac k, treatment retention , Urine specime n collectio n 
& testing , adverse  event and seriou s adverse  event reporting , NYS prescriptio n monitorin g data 
for communit y SLB refill reporting , open- ended interviews with participant s concernin g XRB vs. 
SLB treatmen t satisfactio n and ease-of-use 
XRB Extension  Treatme nt Visits  
Administrativ e data for initial and/or additional  XRB injections, Timeline Followback , Urine specime n 
collectio n & testing , adverse  event and seriou s adverse even reporting. At Visit 7 and 10 , pregnancy 
test, qualitative interviews for eligible XRB participants  
XRB Extension  Final Safety Visit  
Adverse  event and seriou s adverse even reporting. Timeline Followback, Treatment Satisfaction, 
Qualitative Interviews if applicable.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
6  
  
Table of  Contents  
1 - Introduction  ................................ ................................ ................................ ........................  9 
1.1 Introductory Statement  ................................ ................................ ................................ .. 9 
2 - Background  ................................ ................................ ................................ ......................  10 
2.1.1  Preclinical  Experience  ................................ ................................ ...........................  10 
2.1.2  Clinical  Experience  ................................ ................................ ................................  10 
2.2 Background/prevalence of research  topic  ................................ ................................ .... 10 
3 - Rationale/Significance  ................................ ................................ ................................ ..... 11 
3.1 Problem Statement  ................................ ................................ ................................ ...... 11 
3.2 Purpose of Study/Potential  Impact  ................................ ................................ ..............  11 
3.3.1  Potential Benefits ................................ ................................ ................................ ... 13 
3.3.2  Potential Risks  ................................ ................................ ................................ ....... 14 
4 - Study  Objectives  ................................ ................................ ................................ ................  15 
4.1 Hypothesis  ................................ ................................ ................................ ...................  15 
4.2 Primary Objective ................................ ................................ ................................ .........  15 
4.3 Secondary Objectives  ................................ ................................ ................................ .. 15 
5 - Study  Design  ................................ ................................ ................................ ....................  16 
5.1 General Design  ................................ ................................ ................................ ............  16 
5.1.1  Study  Duration  ................................ ................................ ................................ ....... 16 
5.1.2  Number of Study  Sites  ................................ ................................ ..........................  16 
5.2.1  Primary Outcome  Variables  ................................ ................................ ..................  16 
5.2.2  Secondary and Exploratory Outcome  Variables  ................................ ...................  17 
5.3 Study  Population  ................................ ................................ ................................ ..........  17 
5.3.1  Number of  Participants  ................................ ................................ ..........................  17 
5.3.2  Eligibility Criteria/Vulnerable Populatio ns ................................ .............................  17 
6 - Methods  ................................ ................................ ................................ .............................  19 
6.1.1  Identity of Investigational Product/New  Drug  ................................ ........................  19 
6.1.2  Dosage, Admin, Schedule  ................................ ................................ .....................  19 
6.1.3  Method of  Assignment/Randomization  ................................ ................................ . 19 
6.1.4  Blinding and Procedures for Unblinding  ................................ ...............................  19 
6.1.5  Packaging/Labelling  ................................ ................................ ..............................  20 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
7  
 6.1.6  Storage Conditions  ................................ ................................ ................................  20 
6.1.7  Concomitant  therapy  ................................ ................................ .............................  20 
6.1.8  Restrictions  ................................ ................................ ................................ ............  20 
6.2 Assessments  ................................ ................................ ................................ ................  21 
6.2.1  Efficacy  ................................ ................................ ................................ ..................  21 
6.2.2  Safety/Pregnancy -related  policy  ................................ ................................ ...........  21 
6.2.2.1 Adverse Events De finition and  Reporting  ................................ ............................  21 
6.2.3  Pharmacokinetics  ................................ ................................ ................................ .. 23 
6.2.4  Biomarkers ................................ ................................ ................................ .............  23 
6.3 Study  Procedures  ................................ ................................ ................................ ..........  23 
6.3.1  Study  Schedule  ................................ ................................ ................................ ..... 23 
6.3.2  Informed Consent  ................................ ................................ ................................ .. 27 
6.3.3  Screening ................................ ................................ ................................ ...............  27 
6.3.4  Recruitment, Enrollment and  Retention  ................................ ................................  27 
6.3.5  On Study  Visits  ................................ ................................ ................................ ...... 28 
6.3.6  End of Study and  Follow -up ................................ ................................ ..................  30 
6.3.7  Removal of  subjects  ................................ ................................ ..............................  30 
6.4.1  Statistical  Design  ................................ ................................ ................................ ... 30 
6.4.2  Sample Size Considerations  ................................ ................................ .................  31 
6.4.3  Handling of Missing  Data  ................................ ................................ ......................  31 
7 - Trial Administration  ................................ ................................ ................................ ............  32 
7.1 Ethical Considerations  ................................ ................................ ................................ ... 32 
7.2 Institutional Review Board (IRB)  Review  ................................ ................................ .... 32 
7.3 Subject Confidentiality  ................................ ................................ ................................ . 32 
7.4 Deviations/Unanticipated  Problems  ................................ ................................ ............  33 
7.5 Data Quality Assurance  ................................ ................................ ...............................  34 
7.5.1  Data  Collection  ................................ ................................ ................................ ...... 34 
7.5.1.1  Access to Source  ................................ ................................ ...............................  34 
7.5.1.2  Data  Storage/Security  ................................ ................................ ........................  36 
7.6 Study  Records  ................................ ................................ ................................ .............  36 
7.6.1  Retention of  Records  ................................ ................................ .............................  36 
7.7 Study  Monitoring  ................................ ................................ ................................ ..........  37 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
8  
 7.8 Data Safety Monit oring  Plan ................................ ................................ ........................  37 
7.9 Study  Modification ................................ ................................ ................................ ........  37 
7.10 Study  Discontinuation  ................................ ................................ ................................  37 
7.11 Study  Completion  ................................ ................................ ................................ ...... 38 
7.12 Conflict of Interest Policy  ................................ ................................ ...........................  38 
7.13 Funding Source  ................................ ................................ ................................ .........  38 
Appendices  ................................ ................................ ................................ .............................  39 
List of  Tables  ................................ ................................ ................................ ...........................  40 
References  ................................ ................................ ................................ ..............................  41 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
9  
  
1 - Introduction  
1.1 Introductory Statement  
This is a pilot proof -of-concept randomized controlled trial, open -label and  unblinded,  
examining  the feasibility  and acceptability  of Buprenorphine  extended -release  vs. daily 
sublingual  buprenorphine -naloxone  for the treatment  of opioid  use disorder  in jail and at 
community  re-entry.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
10  
  
 
2 - Background  
2.1.1  Preclinical  Experience  
Buprenorphine, a partial μ -opioid receptor agonist, was approved by the Food and  Drug  
Administration in 2002 as office -based pharmac otherapy for opioid dependence. As  an 
opioid  partial  agonist,  buprenorphine  can produce  some  opioid -like effects  such  as euphoria  
or respiratory depression, however, its maximal effects are less than those of full  agonists  
like heroin  and methadone.  At low doses  Buprenorphine  produces  sufficient  agonist  effect  to 
enable  opioid -addicted  individuals  to discontinue  the misuse  of opioids  without  experiencing  
withdrawal symptoms. Buprenorphine's opioid effects increase with each dose until  at 
moderate  doses  they level off, even  with further  dose  increases.  This "ceiling  effect"  lowers  
the risk of misuse, dependency, and side effects  (1). 
2.1.2  Clinical  Experience  
Monthly, injectable, buprenorphine extended -release (XRB, SublocadeTM, Indivior) is  the 
most recently approved pharmacotherapy for opioid use disorders in the U.S.(2). XRB  is 
available as of March -2018 in a pre -mixed subcutaneous formulation, administered  monthly, 
and equivalent to a 16 -24mg/day maintenance dose of sublingual  buprenorphine -naloxone  
(SLB). In this pilot proposal, Buprenorphine extended -release (XRB) or  sublingual 
buprenorphine (SLB) daily maintenance will be provided per usual Opioid  Treatment  
Program  protocols  in-jail and prior to release.  Both medications  will be available  through  the 
study and the Bellevue Hospital Addiction Medicine clinic free -of-charge. XRB consists of  a 
once monthly abdominal subcutaneous injection using a pre -filled syringe, per  usual  
package insert instructions. SLB is a delivered daily by observed dosing in -jail (controlled 
substances are not self -administered in -jail). Post -release, all participants may elect  to 
continue SLB maintenance with the Bellevue Primary Care Addiction Medicine clinic, or  may 
pursue SLB maintenance from non -NYU/Bel levue community providers. SLB is  available  
free of charge  to uninsured  patients  at Bellevue  Hospital  Center,  or participants  may fill SLB 
prescriptions at community pharmacies. SLB medication will not be provided by the  study 
itself.  
2.2 Background/preval ence of research  topic  
In 2016,  opioids  were  involved  in 42,249  deaths  and opioid  overdose  deaths  were  five times  
higher  than in 1999  (3). On average,  115 Americans  die every  day from an opioid  overdose  
(4). The opioid and overdose epidemic has intensified efforts to expand and  optimize  
effective medication treatment for opioid use disorder (methadone, extended -release  
naltrexone,  buprenorphine)  in criminal  justice  and primary  care populations.  Despite  the 
effectiveness  of methadone and buprenorp hine maintenance as standard of care in NYC 
jails, only  about  30% of individuals initiating buprenorphine maintenance in -jail successfully 
link to community treatment post -release. XRB is newly FDA approved and its effectiveness 
in a criminal justice setting is promising but  untested.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
12  
  
 
3 - Rationale/Significance  
3.1 Problem Statement  
The opioid epidemic in the United States continues to worsen. New York City currently has  a 
robust methadone and buprenorphine maintenance program for adults with opioid  use 
disorder (OUD). However, despite these standards -of-care, outcomes for all OUD  patients,  
including buprenorphine patients, in NYC following release from jail are in need  of 
improvement. Overdose rates in NYC c ontinue to worsen, including among  recently 
incarcerated individuals (5). Only about 30% of individuals initiating  buprenorphine  
maintenance for opioid use disorders (OUDs) in -jail currently successfully link to  community 
treatment post -release (6), which has been a finding in a previous NIDA clinical trial  and 
observational studies we have conducted at NYU -Bellevue (7,  8). 
3.2 Purpose of Study/Potential  Impact  
Monthly, injectable, buprenorphine extended -release (XRB, SublocadeTM, Indivior) is  the 
most recently approved pharmacotherapy for opioid use disorders in the US. XRB  is 
available as of March -2018 in a pre -mixed subcutaneous formulation, administered  monthly, 
and equivalent to a 16 -24mg/day maintenance dose of sublingual  buprenorphine -naloxone  
(SLB). 
XRB offers several advantages to other forms of 'medication treatment  for opioid use 
disorders’ (MOUD), which currently consist of daily sublingual buprenorphine  (Suboxone 
films, Zubsolv, or generic buprenorphine -naloxone tablets), daily oral  methadone  
maintenance delivered in Opioid Treatment Programs, or extended -release naltrexone  (XR- 
NTX). None of these earlier medications have proven to be 'killer apps', and uptake of   
MOUD in US correctional facilities (jails, prisons) and community -supervised po pulations  
(drug courts, parole programs) lag the public health need and high overdose risk in these  
settings and populations. Buprenorphine products in particular have been relatively 
shunned in  CJS,  likely due to staffing constraints required by observed induction and daily 
dosing,  concerns regarding diversion and misuse, and common stigmas related to opioid 
agonist  (methadone or buprenorphine) maintenance approaches  (9). 
NYC jails are an exception to this sub -par US CJS standard, in part due to the  current 
leadership  of this proposal's  Co-Investigators  at NYC  Health+Hospitals  Correctional  Health  
Services, Ross MacDonald MD and Jonathan Giftos MD, who are, respectively,  Chief  
Medical Officer and Clinical Director of Substance Use Treatment/Medical Dir ector of  the 
Opioid Treatment Program for all of NYC jails. NYC has a robust methadone  and 
buprenorphine maintenance program for adults with OUD. Despite these  standards -of-care, 
outcomes for all OUD patients, including buprenorphine patients, in NYC follo wing release 
from jail are in need of improvement. Overdose rates in NYC continue to worsen,  including  
among recently incarcerated individuals (5). Only about 30% of individuals  initiating  
buprenorphine maintenance for opioid use disorders (OUDs) in -jail currently  successfully 
link to community treatment post -release (6) which has been a finding in a previous  NIDA  
clinical trial and observational studies we have conducted at NYU -Bellevue (7, 8) .  Major 
obstacles  to office -based  opioid  treatment  (OBOT)  with  MOUD following re -entry include 
limited mobility and communication due to  incarceration,  administrative support for bridging 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
13  
 to a new clinic, high risks of drug/alcohol relapse,  and rigid,  impersonal  treatment  'systems'  
which  are often  not customized  to or welcoming  of the recently  incarcerated.  
The new buprenorphine  extended -release  formulation  (XRB)  has several  potential  feasibility  
and effectiveness  advantages  vs. daily sublingual  buprenorphine  (SLB),  including:  1) fewer  
overall medical, nursing, and pharmacy visits, fewer correctional staff hours, and  potentially  
lower  program  costs  vs. daily  observed  dosing,  2) near zero probability  of diversion/misuse  
vs. frequent diversion, 3) an improved, long -acting 'bridge' of medication adherence  at 
release, which is crucial as patients struggle to continue daily SLB adherence,  avoid  
relapse, and connect to community treatment. The current NYC jail  high-volume  
buprenorphine maintenance program provides an ideal setting in which to pilot XRB  vs. 
SLB.  
Rikers  Island  and the New York City Department  of Corrections  administered  jail system  in 
NYC  is a prominent  exception  to US norms.  NYC  Health+Hospitals  Division  of Correctional  
Health Services, which administers all jail -based health care in NYC,  and has a  high- 
volume program for both continuing existing SLB patients through incarceration  and 
initiating  SLB in new patients  prior to release.  NYC  jails provide  an ideal  setting  in which  to 
pilot jail-based  use of newer  extended -release  buprenorphine  comp ounds.  Two members  of 
NYC  Health+Hospitals  leadership,  are key co-investigators  in this proposal.  This pilot will be 
a first of its kind evaluation  of XRB in a criminal  justice,  underserved  population  at high risk 
or relapse and  overdose.  
3.3.1  Potential Benefits  
This proposal  will likely  be the first or among  the first high-quality  RCT evaluations  of XRB in 
a criminal justice setting. Both XRB and SLB standard of care are safe,  efficacious  
medications for the treatment of OUDs. The expected benefits in the XRB group are  fewer  
medication and nursing visits during incarceration, continuous long -acting  medication 
treatment at release and prior to the first community treatment visit, and potentially a  lower  
risk of relapse to heroin and other drug/alcohol use vs. SLB.  In addition the XRB  is 
delivered free of charge. The SLB treatment -as-usual group will receive the  same 
compensation and encouragement to continue care both in custody and following  release, 
which will be above and beyond u sual care.  Both arms, however, may experience  no 
benefit from study participation, if the medications are not effective, acceptable, or if  post- 
release follow -up is not pursued or completed. The extra XRB medical treatment, pre - and 
post-release counseli ng (both arms), and monetary compensation (both arms) is  intended  
and unlikely  to be coercive  – that is, motivate  persons  to participate  in the trial against  their 
preferences or wishes. These benefits are on par with other recent and approved NYC  jail 
opioid treatment trials which attempt to provide adequate but non -coercive benefits to  all 
participants. The XRB medication free of charge or the modest monetary compensation  is 
unlikely to sway an individual with other good options including jail -based me thadone  and 
buprenorphine  treatment  and no other  interest  in participating  in or following  up during  the 
trial. 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
14  
  
 
3.3.2  Potential Risks  
Any relapse  to illicit opioid  and other  drug and alcohol  use among  any of the two treatment  
arms  after release  from jail (or while  incarcerated)  implies  a risk of death  and disability,  and 
some proportion of participants in all three arms can be expected not to respond  to 
treatment and resume opioid and/or other drug and alcohol use. All participants  relapsing 
post-release and struggling with on -going drug and alcohol use will be counseled  and 
referred  by staff to any appropriate  treatment  modalities,  including  the immediately  available  
addiction services available at Bellevue Hos pital (emergency detoxification with referral  to 
residential treatment or supportive housing, methadone treatment, buprenorphine,  intensive  
outpatient, dual  diagnosis).  
Sublingual Buprenorphine -Naloxone Treatment Arm . The risks of SLB are the usual  risks 
experienced  by any patient  as part of standard  of care buprenorphine  maintenance,  which  is 
first-line treatment for opioid use disorders in NYC jails and in the community.  Persons  
receiving SLB may experience several common side effects such as drowsiness,  dizziness,  
constipation, or headaches. The SLB arm will otherwise not be exposed to risks  beyond  
those  of usual  care,  which  will be provided  by existing  jail and community  partners.  Further,  
participants in the SLB arm will have already agreed to these risks and benefits of an  SLB 
treatment program prior to recruitment and enrollment, as their choice to engage in jail  SLB 
will have been established well before enrollment, which will occur at the end of  the 
incarceration  period.  
Buprenorphine  Extended -Release  Treatment  Arm. XRB carries  the same  potential  systemic 
buprenorphine -related  side effects  as SRB.  XRB also carries  risks from the injection.  
Injection site soreness is possible and usually well tolerated. More severe injection  site 
reactions, although rare, include swelling, itching, and pain. All injections sites will  be 
inspected and monitored by study  clinicians.  
Concomitant use of buprenorphine and benzodiazepine or other CNS  depressants  
increases the risk of adverse reactions in cluding overdose, respiratory depression,  and 
death.  Urine  toxicology  biometric  tests  will be used  to ensure  persons  receiving  both SLB 
and XRB have not taken any other substances. Participants will be educated regarding  the 
risks of concomitant  use of benzodiazepines,  sedatives,  opioid  analgesics  and alcohol.  
Additionally, if a participant requires opioids for any medical treatment once  on 
buprenorphine,  they will likely  not have  adequate  pain relief  from usual  doses  of opioid  pain 
medications. Particip ants should tell the treating clinician that they are participating in  this 
clinical study and will need non -opioid pain relief or higher doses of opioid pain  medications 
for their condition, which they should receive only in a monitored medical setting, such as  an 
emergency  room.  As a result,  participants  may experience  higher  level of pain.  
Risk/Benefit  Ratio:  Most  of the risks described  are expected  adverse  events  associated  with 
XRB and SLB,  or those  of baseline  opioid  dependence  and jail-to-community  ETAU  or MTP.  
The risks of the active treatment arms, XRB and SLB are likely small compared to  the 
expected benefit of discontinuing opioid  use. 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
15  
  
 
4 - Study  Objectives  
4.1 Hypothesis  
Primary Aim hypothesis: We hypothesize that XRB will be a feasible, effective,  and 
preferred/accepted  medication  assisted  therapy  for OUDs  in jail as compared  to SLB.  
Secondary  Aim 1 hypothesis:  We hypothesize  that XRB will be more  effective  in improving  
rates  of community  treatment  initiation/continuation  post-release  as compared  to SLB.  
Secondary  Aim 2 Hypothesis:  We hypothesize  that XRB will be more  effective  in decreasing  
illicit opioid use post -release as compared to  SLB.  
Secondary Aim 3 Hypothesis: We hypothesize that the use of  XRB vs. SLB will lead  to 
better outcomes in the context of XRNTX, ETAU, and Methadone outcomes accrued in  the 
larger SOMATICS -XOR  RCT.  
4.2 Primary Objective  
Feasibility  and Implementation:  Estimate  the feasibility  and ease  of use of XRB vs. SLB as 
measured  by initial  patient  preference  and acceptability,  in-treatment  patient  satisfaction, 
patient qualitative interviews,  jail visit frequency and program cost estimates, and rates of 
medication  diversion.  
4.3 Secondary Objectives  
Treatment  Retention:  Estim ate the effectiveness  of XRB vs. SLB in improving  rates  of 
community treatment initiation/continuation  post-release.  
Clinical  Effectiveness:  Estimate  the effectiveness  of XRB vs. SLB in decreasing  illicit opioid  
(e.g. heroin) use  post-release.  
Naturalistic  Comparative  Effectiveness:  Evaluate  outcomes  of XRB vs. SLB in the context  of 
the XRNTX,  ETAU,  and Methadone  outcomes  accrued  in the larger  SOMATICS -XOR  RCT.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
16  
  
 
5 - Study  Design  
5.1 General Design  
This is a phase  IV, 8 week,  pilot proof -of-concept  randomized  controlled  trial, open -label  and 
unblinded  of XRB vs SLB (N=50)  that takes  advantage  of the existing  SOMATICS -XOR  U01 
(NIDA) trial  design.  
5.1.1  Study  Duration  
This is an 8 week pilot  RCT.  
The study has received 50 doses of in -kind SublocadeTM study medication from the 
manufacturer, Indivior as of September 13, 2019. With this new stock of medication, we 
would like to offer all participants the option of a therapeutic treatment extension of 24 
weeks post study visit 5 week 8. Active treatment w ill continue after the Week 8 study visit 
through Week 20 wherein participants will be eligible to receive initial and/or additional XRB 
injections. A safety visit, in which no medication is administered, will be conducted at Week 
24 to document safety rep orting and provide post -study treatment referrals.  
This 24 week therapeutic extension will be offered to all interested participants regardless of 
their treatment assignment after the completion of Visit 5 Week 8. Only SublocadeTM 
injections will be offere d, no additional forms of compensation will be provided.  
5.1.2  Number of Study  Sites  
This is a multi -site pilot, RCT. Participants (N=50) will be recruited from Rikers Island  NYC  
Jail and will then complete  all follow -up visits  at Bellevue  Hospital  Center  in NYC. The NYU 
School of Medicine Institutional Review Board (IRB) is serving as the IRB of record for 
Health+Hospitals involvement in this research study.  
Sites : The NYC jail system houses approximately 8,000 -9,000 inmates daily in 11+  inmate  
facilities, 8 o f which are located on Rikers Island. Most (90%) are adults detained  on  
charges or sentenced to misdemeanor charges and likely to leave jail and return to  the 
community following an average pretrial detention of several weeks or after serving  a 
misdemeano r sentence of less than one year. The jail Opioid Treatment Program  primarily  
operates at three facilities, a male admission facility (Anna M Kross Center), a  male 
sentenced -inmate facility (Eric M Taylor Center), and a single female facility (Rose M  Singe r 
Center),  all located  on Rikers  Island  in the Bronx.  For the purposes  of this pilot,  participants  
will be recruited from the Eric M Taylor Center and the Rose M Singer Center. The  jail 
Opioid Treatment Program currently treats around 100 -200 patients daily with  sublingual 
buprenorphine,  this pilots  target  population,  and 500-800 daily with methadone  maintenance.  
All  follow -up  will  be  conducted  at  the  Bellevue  Hospital  Center's  Adult  Primary                  
Care Clinic and its Addict ion Medicine clinic, which is currently a routine aftercare referral  for 
jail patients continuing buprenorphine in the community and the site of the current  NYU - 
NIDA  U01 XOR  trial. Patient’s  lost-to-follow -up and out-of-contact  are tracked  by study  staff 
in the community whenever possible, including in -person door -knocking by Study  Staff  
throughout the 5 boroughs and northern New  Jersey.  
5.2.1  Primary Outcome  Variables  
The primary  outcome  of in-jail feasibility  and acceptability  will be measured  by the percent  of 
eligible participants who enroll in the study, the mean medical/medication visits per arm  and 
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
17  
 per participant, rates of medication diversion, and open -ended interviews with  patients  
regarding treatment satisfaction and ease of  use. Additional qualitative interviews will be 
conducted with eligible participants to further examine opioid use disorder treatment with 
extended -release buprenorphine, in -jail and within the community.  
5.2.2  Secondary and Exploratory Outcome  Variables  
Seconda ry Aims 1 -3 will be measured utilizing the following assessments:  baseline  
demographics, baseline ASI -Lite, baseline MOUD (medication treatment for opioid use 
disorder) exposure/preference, Timeline Followback, urine  toxicology  results, treatment 
retention , and NYS Prescription Monitoring Data. XRNTX, ETAU,  and Methadone outcomes 
will be taken from the SOMATICS -XOR U01 parent  study.  
5.3 Study  Population  
Adult jail inmates with upcoming release date, current opioid dependence and  currently 
maintained on sublingu al buprenorphine -naloxone  (N=50).  
5.3.1  Number of  Participants  
N=50.  A total sample  size of N=50  would  allow  for an estimate  of an Odds  Ratio  of 2.0-3.0 
for the rate of persons successfully in community buprenorphine treatment at 4 weeks  post- 
release (71% vs. 30% success favoring XRB; two -sided alpha of 0.05; 80+%  power).  
5.3.2  Eligibility Criteria/Vulnerable Populations  
Inclusion  criteria  
1) Adults >18yo incarcerated in NYC jails with known release  dates.  
2) DSM -V criteria for current opioid use disorder (DSM -IV opioi d dependence).  
3) Currently maintained on sublingual buprenorphine -naloxone in the NYC jail  opioid  
treatment program.  
Exclusion  Criteria  
1) Individual  not interested  in XRB treatment.  Current  SLB patients  are otherwise  by 
definition appropriate for  XRB.  
2) Pregnant or planning conception. As female participants are incarcerated & active in the 
jail opiate treatment program at the time of baseline assessments and treatment induction, a 
pregnancy test is not required by the study staff. A urine dipstick pregna ncy (hCG) test will  
be administered  at week 4 visit 3.  The test detects  human  chorionic  gonadotropin  (hCG)  in 
urine  with a sensitivity/specificity of: 25 mIU hCG/ml, >99%. Time to result is four minutes. If  
negative,  a urine  pregnancy  test will be administ ered at the final week 8 visit 5  and final week 
20 visit 8 (if applicable) to ensure  that a participant  is not  pregnant.  
3) No severe  or acute  medical  or psychiatric  disability  preventing  safe study  participation  or 
making follow -up unlikely.  
Federal Research among Prisoners . Study participants are clearly considered prisoners  at 
the time of enrollment.  The NYU SOM IRB will contact DHS/OHRP to address this  topic  
and for permission to enroll prisoners in a federally funded research trial. However,  we 
believe this study carefully conforms to the Federal guidelines for research among  prisoners  
(CFR 46.306) in the following  manner:  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
18  
 1.) Research on practices, both innovative and accepted, which have the intent  and 
reasonable  probability  of improving  the health  or well-being  of the subject.  In cases  in which  
those studies require the assignment of prisoners in a manner consistent with  protocols  
approved by the IRB to control groups which may not benefit from the research, the  study 
may procee d only after the Secretary has consulted with appropriate experts,  including  
experts in penology medicine and ethics, and published notice, in the Federal Register,  of 
his intent to approve such  research.  
2) Any possible  advantages  accruing  to the prisoner  through  his or her participation  in the 
research, when compared to the general living conditions, medical care, quality of  food,  
amenities  and opportunity  for earnings  in the prison,  are not of such  a magnitude  that his or 
her ability  to weigh  the risks of the research  against  the value  of such  advantages  in the 
limited choice environment of the prison is impaired. Incentives and benefits  from 
participation  are not coercive  and are fair value  of participant's  time and, following  release, 
travel.  
(3) The risks involved in the research are commensurate with risks that would be  accepted  
by non -prisoner volunteers. This study's methods and interventions are consistent with  good  
clinical practices in community  settings.  
(4) Procedures for the selection of subjects within the prison are fair to all prisoners  and 
immune  from arbitrary  intervention  by prison  authorities  or prisoners.  Unless  the principal  
investigator  provides  to the Board  justification  in writing  for following  some  other  procedures,  
control subjects must be selected randomly from the group of available prisoners who  meet 
the characteristics  needed  for that particular  research  project.  Jail authorities  have  no role in 
this study or in treatment assignment, which is  random.  
(5) The information is presented in language which is understandable to the  subject 
population.  The informed  consent  and consent  quiz are intended  to be understandable  to 
adults in  jail. 
(6) Adequate assurance exists that parole boards will not take into account a  prisoner's  
participation in the research in making decisions regarding parole, and each prisoner  is 
clearly  informed  in advance  that participation  in the research  will have  no effect  on his or her 
parole; There is no role for, relationship, or ot her interaction with parole or  probation  
authorities and this  study.  
(7) Where the Board finds there may be a need for follow -up examination or care  of 
participants  after the end of their participation,  adequate  provision  has been  made  for such 
examination or care, taking into account the varying lengths of individual  prisoners'  
sentences, and for informing participants of this fact. The study primarily consists  of 
community follow -up of adults released from NYC jails. Follow -up  consists of  research 
visits conducted weekly then bi -weekly for both medication arms post -release (week 1  post- 
release, week 2, week 4, week 6, week  8). After the completion of Visit 5 Week 8, all 
participants will be eligible for a 24 week therapeutic extension study wh erein they are 
offered initial and/or additional XRB injections. These will occur monthly post study week 8: 
week 12, week 16, week 20, week 24, and week 28. A final safety  visit, no medication 
administered, will be conducted at week 32 to document safety reporting and provide post -
study treatment referrals.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
19  
  
 
6 - Methods  
6.1.1  Identity of Investigational Product/New  Drug  
Monthly, injectable, buprenorphine extended -release (XRB, SublocadeTM, Indivior) is  the 
most  recently  FDA approved  pharmacotherapy  for opioid  use disorders  in the U.S.(2).  XRB 
is available as of March -2018 in a pre -mixed subcutaneous formulation,  administered  
monthly, and equivalent to a 16 -24mg/day maintenance dose of sublingual  buprenorphine - 
naloxone (SLB). Sublingu al buprenorphine was approved by the FDA in 2002 and  is 
delivered  daily by placing  the medication  under  the tongue  for 5 to 10 minutes  and letting  it 
dissolve  completely.  
6.1.2  Dosage, Admin,  Schedule  
Buprenorphine Extended Release: XRB is a 300mg or 100mg pre -mixed subcutaneous  
injectable  formulation to be administered monthly. XRB is for abdominal subcutaneous 
injection  only.  Participants  in the XRB treatment  arm will be given  1 or more  XRB injections  
prior to release from  jail and one or more  at weeks  4, 8, 12, and 16  post-release,  depending  
on their release  date.  
Sublingual Buprenorphine: SLB (SUBOXONE, Zubsolv, or generic tablets) is a  daily 
sublingual film or tablet ranging from 8-24mg/day or equivalent (Zubsolv is dosed  5.7-17.1 
mg/day). The film or tablet is placed under the tongue for 5 to 10 minutes until  dissolved  
completely. Participants in the SLB treatment arm will be provided SLB daily by  observed  
dosing in -jail (controll ed substances are not self -administered in -jail) and encouraged  to 
continue SLB treatment in weekly, bi -weekly, or monthly quantities for unobserved,  daily,  
self-administration through week 5. Patients may obtain SLB care free -of-charge from  the 
Bellevue  Hospital  Center  Addiction  Medicine  clinic  or from non-NYU/Bellevue  providers  and 
pharmacies per usual care  standards. After the completion of Visit 5 Week 8, SLB 
participants will be offered XRB treatment in the 20 week therapeutic extension. If 
interested,  participants would receive one or more XRB injections during the period of 
Weeks 8, 12, 16, 20, 24, and 28 followed by a final safety documentation visit at Week 32.  
6.1.3  Method of  Assignment/Randomization  
Screening and  Randomization  
This pilot will recruit from within the standard -of-care NYC jail opioid treatment program,  led 
by the program director, Jonathan Giftos, MD. Potential participants currently maintained  on 
sublingual buprenorphine (currently a NYC jail standard of care) will be offered  study 
information and encouraged to enroll. Interested participants will be referred by the  Opioid  
Treatment Program staff to Study Staff for further education about the trial and to  schedule 
written informed consent and a comprehensive screening visit. Cons ented and  eligible  
participants will be randomized by sealed envelope or a web -based randomizer 1:1 to the  2 
study cells: XRB and  SLB.  
6.1.4  Blinding and Procedures for  Unblinding  
This is an 8 -week, open -label, single site, proof -of-concept randomized controlled  trial. 
There  is no blinding  of treatment  assignment  or of outcomes  assessments.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
20  
 6.1.5  Packaging/Labeling  
Buprenorphine Extended Release (SUBLOCADE): XRB is available in dosage strengths  of 
100 mg/0.5  mL and 300 mg/1.5  mL buprenorphine.  Each  dose  is provided  in a prefilled  
syringe with a 19 gauge 5/8 -inch needle. The recommended dose of XRB  following  
induction  and dose  adjustment  with transmuscosal  buprenorphine  is 300 mg monthly  for the 
first two months followed by a maintenance dose of 100 mg or 300 mg monthly. We will  offer 
both 300mg and 100mg  doses  pre-release  and at week 4 post -release.  Each dose is 
supplied in an individual kit and will be acquired  in bulk shipments from the supplier  Indivior.  
At the outset of this study and original IRB approval, it was proposed that each participant 
randomized to the XRB (SUBLOCADE) treatment arm would receive up to two injections of 
XRB, each 300mg according to the medication package insert. However, the stud y has 
since been modified to include a therapeutic treatment extension of 24 additional weeks 
post Visit 5 Week 8 in which initial and/or additional XRB injections would be offered to all 
interested participants (see section 5.1.1). With this therapeutic e xtension, eligible & 
interested participants could receive 4+ XRB injections in the community. With this in mind, 
the study must expand the planned XRB dosage to include the 100mg formulation of XRB. 
As the XRB package insert states, the recommended dose o f XRB following induction is 
300mg monthly for the first two months followed by a maintenance dose of 100mg or 
300mg monthly. The study must have the capability to offer eligible participants receiving a 
third XRB injection the lower, recommended maintenan ce dose of 100mg in addition to the 
standard 300mg.  
Sublingual Buprenorphine (SUBOXONE, Zubsolv, or generic tablets): SLB is  administered  
sublingually or buccally as a single daily dose. Medication should be prescribed  in 
consideration of the frequency of  visits. Provision of multiple refills is not advised in  early  
treatment or without appropriate follow -up visits. After treatment induction and  stabilization, 
the maintenance  dose  of SLB is generally  in the range  of 4mg/1mg  buprenorphine/naloxone  
to 24mg/6 mg buprenorphine/naloxone per day depending on the individual patient  and 
clinical response, as determined by the clinician. Daily doses will vary by individual.  The 
recommended target dose of SLB during maintenance is  16mg/4mg  
buprenorphine/naloxone. SLB will be prescribed and provided via observed dosing  in-jail 
(controlled substances are not self -administered in -jail) per usual care protocols.  Post- 
release, all participants may elect to continue SLB maintenance with the Bellevue  Primary  
Care Addiction Medicine clinic, or may pursue SLB maintenance from  non-NYU/Bellevue  
community providers. SLB is available free of charge to uninsured patients at  Bellevue  
Hospital Center, or participants may fill SLB prescriptions at community pharmacies.  SLB 
medication will not be provided by the study itself. Self -report, BHC EMR records, and  NYS 
Prescription Monitoring Plan audits will document SLB post -release community  treatment  
retention, daily dose, and refill  frequencies.  
6.1.6  Storage Conditions  
XRB Storage C onditions: Store refrigerated at 2 - 8ºC (35.6 - 46.4ºF). Once outside  the 
refrigerator XRB may be stored in its original package at room temperature 15 -30ºC (59  - 
86ºF), for up to 7 days prior to  administration.  
SLB Storage  Conditions:  Store  at room  temperature  between  20 - 25ºC  (68 - 77ºF).  
6.1.7  Concomitant  therapy  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
21  
 It is advisable for both XRB and SLB treatment arms that patients refrain from use  of 
benzodiazepines,  sedatives,  tranquilizers,  antidepressants,  stimulants,  or alcohol.  Urine  
toxicology will be collected at medication dispensation visits in order to ensure  no 
contraindications.  
6.1.8  Restrictions  
XRB Restrictions: For abdominal subcutaneous injection only. Do not administer  XRB 
intravenously  or intramuscularly.  Only a healthcare  provider should  prepare  and administer  
XRB. Administer monthly with a minimum of 26 days between  doses.  
SLB Restrictions:  Take  the prescribed  dose  once  a day. SLB must  be taken  whole.  Do not 
cut, chew, or swallow. SLB film should not be moved after placement. Proper  administering  
technique  should  be demonstrated  to the patient  by a healthcare  provider.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10 
20  
  
 
6.2 Assessments  
Measures and  Assessments:  
a) Baseline assessments include a drug and alcohol use history (ASI -Lite), a  pre-arrest   
recall of drug and alcohol use (Timeline Followback), a medication treatment for opioid use 
disorder exposure/preference form (MOUD preference), demographic information, and  jail 
Electronic  Medical  Record  medical  and psychiatric  history  and laboratory  data,  including  HIV 
and HCV status.  
b) In-jail feasibility assessments of XRB vs. SLB include logging the % eligible enrolling  in 
the study; the density of medical/nursing/pharmacy visits per arm and per participant;  the 
incidence  rates  of medication  diversion;  open -ended  interviews  with participants  surrounding 
XRB vs. SLB and ease -of-use and  satisfaction;  
a) Post-release follow -up assessments include administrative data for SLB medication  refills 
and post -release XRB injections, self -reported  opioid and other drug use  (Timeline 
Followback), urine toxicology testing, pregnancy testing, treatment retention (treatment 
retention form),  Adverse  Event and Serious Adverse Event monitoring (SAFTEE), and NYS 
Prescription  Monitoring Data for community S LB pharmacy refill  reporting. The I -STOP/PMP 
(prescription monitoring program) registries will be accessed in order to track participant 
data related to respective treatments. Additional qualitative interviews will be conducted with 
eligible XRB participan ts to further examine opioid use disorder treatment with extended -
release buprenorphine, in -jail and within the community . 
6.2.1  Efficacy  
The primary  outcome  of in-jail feasibility  and acceptability  will be measured  by the percent  of 
eligible participants who enroll in the study, the mean medical/medication visits per arm  and 
per participant,  the incidence  rates  of medication  diversion,  and open -ended  interviews  with 
patients regarding treatment satisfaction and ease of  use. 
Secondary Aims 1 -3 will be measured utilizing the following assessments:  baseline  
demographics, baseline ASI -Lite, baseline MOUD exposure/preference,  Timeline 
Followback, urine  toxicology  results, treatment retention, and NYS Prescription Monitoring 
Data. XRNTX, ETAU,  and Methadone outcomes will be taken from the SOMATICS -XOR 
U01 parent  study.  
6.2.2  Safety/Pregnancy -related  policy  
XRB and SLB are both FDA approved, safe, efficacious medications for the treatment  of 
opioid use disorder. As with most medications both XRB and SLB carry side effects  as 
detailed  above.  Participants  will be monitored  throughout  this pilot RCT by study  physicians,  
all adverse  events  and/or  serious  adverse  events  will be documented  and medication  will be 
discontinued if necessary. Women who are pregnant  or plan to become pregnant will  be 
excluded from this pilot  RCT.  
6.2.2.1  Adverse Events Definition and  Reporting  
For the purposes of this pilot, proof -of-concept, RCT, an adverse event (AE) is  any 
symptom, sign, illness or experience that develops or worsens in severity during the  course 
of the study.  Intercurrent  illnesses  or injuries  should  be regarded  as adverse  events.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
21   
 
Abnormal  results  of diagnostic  procedures  are considered  to be adverse  events  if the 
abnormality:  
• results in study  withdrawal  
• is associated with a serious adverse  event  
• is associated with clinical signs or  symptoms  
• leads to additional treatment or to further diagnostic  tests  
• is considered by the investigator to be of clinical significance (i.e. medication  side 
effects)  
All adverse  events  will be documented  in the attached  clinical  research  form and reported  to 
the IRB where  necessary.  
A serious adverse event (SAE) is any AE that  is: 
• fatal 
• life-threatening  
• requires or prolongs hospital  stay 
• results in persistent or significant disability or  incapacity  
• a congenital anomaly or birth  defect  
• an important medical  event  
Important medical events are those that may not be immediately life threatening, but  are 
clearly of major c linical significance. They may jeopardize the subject, and may  require 
intervention  to prevent  one of the other  serious  outcomes  noted  above.  For example,  drug 
overdose or abuse, a seizure that did not result in in -patient hospitalization, or  intensive  
treatment of bronchospasm in an emergency department would typically be  considered 
serious.  
All serious adverse events will be documented in the attached clinical research form  and 
reported to the IRB where  necessary.  
Classification  of an Adverse  Event:  for AEs in this pilot RCT the following  guidelines  will be 
used to describe  severity.  
• Mild — Events require minimal or no treatment and do not interfere with  the 
participant's daily  activities.  
• Moderate — Events result in a low level of inconvenience or co ncern with  the 
therapeutic measures. Moderate events may cause some interference  with 
functioning.  
• Severe — Events interrupt a participant's usual daily activity and may  require 
systemic  drug therapy  or other  treatment.  Severe  events  are usually  potentially  life- 
threatening or incapacitating.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
22   
 
Relationship  to Study  Medication:  To assess  whether  an AE may be associated  with the 
study medication (XRB vs. SLB) the following guidelines will be  used:  
 
 
• Definitely Related — There is clear evidence to suggest a causal relationship,  and 
other possible contributing factors can be ruled out. The clinical event, including  an 
abnormal laboratory test result, occurs in a plausible time relationship to  drug 
administration and cannot be explained by concurrent disease or other drugs  or 
chemicals. The response to withdrawal of the drug (dechallenge) should be  clinically 
plausible. The event must be pharmacologically or phenom enologically  definitive,  
with use of a satisfactory rechallenge procedure if  necessary  
• Probably Related — There is evidence to suggest a causal relationship, and  the 
influence of other factors is unlikely. The clinical event, including an  abnormal  
laboratory test result, occurs within a reasonable time after administration of  the 
drug, is unlikely to be attributed to concurrent disease or other drugs or  chemicals, 
and follows a clinically reasonable response on withdrawal  (dechallenge). 
Rechallenge information is not required to fulfill this  definition.  
• Possibly Related — There is some evidence to suggest a causal relationship  (e.g., 
the event occurred within a reasonable time after administration of the  trial 
medication). However, other factors may have contributed to the event (e.g.,  the 
participant's clinical condition, other concomitant events). Although an AE may  rate 
only as "possibly related" soon after discovery, it can be flagged as requiring  more 
information and later be upgraded  to "probably related" or "definitely related,"  as 
appropriate.  
• Unlikely  to be related  — A clinical  event,  including  an abnormal  laboratory  test result, 
whose temporal relationship to drug administration makes a causal  relationship 
improbable (e.g., the event did not occur within a reasonable time  after  
administration of the trial medication) and in which other drugs or chemicals  or 
underlying disease provides plausible explanations (e.g., the participant's  clinical 
condition, other concomitant  treatment s). 
• Not Related — The AE is completely independent of study drug  administration,  
and/or  evidence  exists  that the event  is definitely  related  to another  etiology.  There  
must be an alternative, definitive etiology documented by the  clinician.  
Study clinician s will be responsible for determining whether an AE is expected  or 
unexpected.  An AE will be considered  unexpected  if the nature,  severity,  or frequency  of the 
event  is not consistent  with the risk information  previously  described  for the study  agent.  
The pilot study  team  will record  all reportable  events  with start dates  occurring  any time after 
informed consent is obtained until 7 (for non -serious AEs) or 30 days (for SAEs) after  the 
last day of study participation. At each study visit, the investigator will inquire about  the 
occurrence of AE/SAEs since the last visit. Events will be followed for outcome  information  
until resolution or  stabilization.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
23   
 
6.2.3  Pharmacokinetics  
Not applicable.  
6.2.4  Biomarkers  
Not applicable.  
6.3 Study  Procedures  
The study procedures are detailed  below.  
6.3.1  Study  Schedule  
The total number of expected visits per participant is 6 visits. All participants will be given 
the option to participate in a 24 week therapeutic extension study of XRB treatment 
following  completion of Visit 5 Week 8. If a participant elects to continue and/or initiate XRB 
treatment, there will be 12 total visits per participant. The average time needed  to complete 
each visit will be approximately one hour. The initial week 0 screening  and randomization 
visit will be conducted in a Rikers Island jail facility in the Opioid  Treatment  Program. Once 
consented, enrolled, and randomized, buprenorphine  extended -release  (XRB) or sublingual 
buprenorphine (SLB) daily maintenance will provided per us ual Opioid  Treatment Program 
protocols in -jail and prior to release. The timing between  randomization and release will 
vary. Typical misdemeanor sentences in NYC are 30 -60 days,  and participants  may 
randomize  at any time during  this incarceration  period,  begin  XRB vs. SLB treatment, and 
then leave jail after weeks -to-months. This variable, naturalistic,  in-custody  study period 
remains Study Week 0.  Study Week 1 commences with the day of  release from jail. Post -
release, all study visi ts will be conducted at Bellevue Hospital Center's  (BHC) Addiction 
Medicine clinic. Medical and research visits will be conducted weekly and then  bi- weekly for 
both medication arms post -release (week 1 post -release, week 2, week 4,  week  6, week 8). 
The me dication schedule for both arms is as  follows:  
Buprenorphine Extended -Release: Participants randomized to this arm will receive at   least  
two doses of XRB. The first will be administered at study week 0 in -jail, at least one  week  
prior to release. Particip ants incarcerated for greater than 4 weeks following  randomization 
will receive 2+ XRB doses prior to release. Post -release, XRB injections will  be administered  
at study  week  1-16 in the BHC  Addiction  Medicine  clinic  depending  on the timing of the 
previous pre -release/community  injections.  
Sublingual Buprenorphine: Participants randomized to this arm will be provided SLB  daily 
maintenance per usual Opioid Treatment Programs protocols in -jail. Post -release, SLB  arm 
participants wil l receive follow -up care at Bellevue Hospital’s Addiction Medicine or at  non- 
BHC/NYU community providers, per their preference. We expect and will encourage  most 
participants to follow -up at Bellevue, though this is not mandated. Typically an initial  week 's 
supply of SLB is prescribed within one week of release. At visit 2, week 2, SLB  participants  
typically refill a two week's supply of daily maintenance SLB. SLB participants will  continue 
to receive 2 -4 week refill prescriptions for SLB from visit 2, wee k 2 through visit 6, week  8. 
Regardless  of SLB prescribing  patterns,  they are encouraged  to attend  study  follow -up visits 
at BHC per the same study schedule (Weeks  1,2,4,6,8). After the completion of Visit 5 
Week 8, SLB participants will be offered XRB treatment in the 24 week therapeutic 
extension. If interested, participants would receive one or more XRB injections during the 
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
24  period of Weeks 8, 12, 16, 20, 24, and 28 followed by a final safety documentation visit at 
Week 32.  
For both treatment  arms,  urine  toxicology  tests  will be conducted  at all follow -up visits  at the 
BHC Addiction Medicine Clinic in order to detect any illicit substance use as well  as 
buprenorphi ne adherence.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
25  STUDY  SCHEDULE  
Test/Procedures  Screening/  
Randomization  Treatment Period &  Follow -Up XRB 20 Week Treatment & Follow -Up 
Study Visit  Number  0 1 2 3 4 5 6 7 8 9 10 11 
Week  0 1 2 4 6 8 12 16 20 24 28 32 
Informed Consent  1 X            
HIPAA  2 X            
Locator  Form  X            
Medical  History  X            
Psychological History  X            
Physician Progress  Note  X X X X X X X X X X X X 
Confirm  Eligibility  X            
Randomization  X            
Adverse Event  Forms  
(AE, SAE, BUP  
specific  AE)   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
Clinical Assessment  
of Intervention  3      X      X 
Urine  Toxicology   X X X X X X X X X X X 
Pregnancy  Test    X  X  X   X  
Demographics  X            
MOUD 
History/Preference  X            
ASI-Modified 
Lifetime/CJS -Baseline  X            
Timeline  Followback  X X X X X X X X X X X X 
Inmate Lookup Form4  X X X X X       
New Arrests and Days 
Incarcerated Form4  X X X X X       
Overdose Form   X X X X X X X X X X X 
XR-B Administration 
Form  X   
 
 
 
 X   X X X X X  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
26  NYS Prescription  
Monitoring Data  
(SLB - Only)    
X  
X  
X  
X  
X       
Dispense  
Study  
Medications5 X, # X, # X, # X, # X, # X X X     
Treatment  Retention   X X X X X       
Open -
Ended  
Interviews6  
X    X       
Qualitative 
Interviews7  
    X  
X X  
X  
Treatment 
Satisfaction 
Form       
X   
   
X 
Annotations:  
1. All patients  must  sign an informed  consent  consistent  with ICH-GCP  guidelines  prior to 
participation  in this trial, which  includes  performing  any screening  procedures,  medication 
washout and any  restrictions.  
2. HIPAA authorization must be obtained on all patients participating in the study at  Visit1.  
3. Clinical  Assessment  must  be completed  per protocol  instructions  and by the treating  
investigator for t hat specific  patient.  
4. These instruments will be available for each visit, however they may/may not be filled out   
       depending on participant ’s interaction with CJS  
5.    X = XRB, # = SLB; dispensation schedule varies depending on release date  
6.    Open -Ended interview should occur at participant ’s first & final community visit  
7.    For eligible XRB participants only, occurs at week 8 and final community visit.        
 
 
 
 
 
 
 
 
 
 
 
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
27   
6.3.2  Informed Consent  
Potential participants interested in buprenorphine maintenance (currently a NYC  jail 
standard  of care)  will be offered  study  information  and encouraged  to enroll.  The study  
team  will receive  IRB-approval  for all study  documents,  informational  handouts,  informed  
cons ent forms, informed consent quizzes, and all CRFs prior to screening and  
randomizing participants.  Consent  forms  describing  in detail  the study  agent,  study  
procedures,  and risks are  given  to the participant  and written  documentation  of informed  
consent  is required  prior to starting  intervention/administering  study  product.  Written  
informed  consent  including  a consent quiz adapted from the parent grant protocol will be 
used to document  informed  consent. Participants will have the opportunity to ca refully 
review the written consent  form and ask questions prior to signing. The participants may 
withdraw consent at any  time throughout the course of the trial. A copy of the signed 
informed consent document will  be given  to the participants  for their records.  The rights  
and welfare  of the participants  will be protected  by emphasizing  to them  that the quality  
of their medical  care will not be adversely  affected if they decline to participate in this  
study.  
A copy of the signed informed consent doc ument will be stored in the subject's  research 
record.  The consent  process,  including  the name  of the individual  obtaining  consent,  will be 
thoroughly documented in the subject's research record. Any alteration to the  standard 
consent process (e.g. use of a translator, consent from a legally authorized  representative, 
consent  document  presented  orally,  etc.) and the justification  for such  alteration  will likewise  
be documented.  
6.3.3  Screening  
Potential participants will meet with study staff to learn about st udy procedures,  
buprenorphine (XRB and SLB) treatment, and follow -up protocols. A pre -screen  checklist 
will evaluate eligibility. All adult jail inmates with an upcoming release date, current  opioid  
use disorder diagnosis, and currently maintained on subli ngual buprenorphine -naloxone  will 
be potential participants. If interested and eligible, participants will complete the  informed  
consent process (ICF and ICF quiz). Once informed consent is obtained,  baseline  
assessments  will be administered  prior to randomization.  The baseline  assessments  include  
a drug and alcohol use history (ASI -Lite), demographics, a pre -arrest recall of drug  and 
alcohol use (Timeline Followback), prior medication treatment for opioid use disorder 
exposure and preferences (MOUD Pr eference form), and jail Electronic Medical Record 
medical  and psychiatric  history  and laboratory  data,  including  HIV and HCV  status.  
6.3.4  Recruitment, Enrollment and  Retention  
Recruitment:  Adult  inmates  with known  Department  of Corrections  release  dates  and recent 
or on-going  opioid  treatment  are housed  in two NYC  jail facilities,  both on Rikers  Island;  the 
Eric M. Taylor Center (male) and the Rose M Singer Center (female). Approximately  150 
persons  a month  leave  this facility  with an opioid  use disorder  diagnosis  and on active  OUD  
treatment (e.g. buprenorphine, methadone, naltrexone, or counseling). NYULMC study  staff 
with NYC Health+Hospitals clinical credentials and HHC -approved access to  Rikers  
electronic  medical  record  database  (EMR)  will search  for opioid  dependent  diagnoses,  in-jail 
opioid treatment program participation and pending release dates of potential  participants  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
28  located  in this housing  unit. Potential  participants  interested  in buprenorphine  maintenance 
(currently a NYC jail sta ndard of care) will be offered study information and encouraged  to 
enroll. As current daily maintenance of sublingual buprenorphine is required in order to  be 
eligible  for this pilot,  participants  will be already  be affiliate  with the in-jail Opioid  Treatm ent 
Program  and will be referred  by the Opioid  Treatment  Program  staff to Study  Staff for further  
education about the trial and to schedule written informed consent and a  comprehensive 
screening visit. Monetary compensation for time and travel are intended to facilitate  and 
encourage follow -up visit attendance; transportation services for follow -up visits  are 
otherwise not  provided.   
 
Informed Consent and Enrollment/Randomization: Study staff will obtain informed  consent 
via the completion of the in formed consent form and informed consent quiz. Consented  and 
eligible participants will be randomized by sealed envelope or a web -based randomizer  1:1, 
XRB vs. SLB. Medications will be dispensed at the screening/randomization visit in -jail (visit 
1, week 0) for both arms. All follow -up visits (visit 1 -6) will take place at Bellevue  Hospital  
Center's  Addiction  Medicine  clinic  and medication  (XRB)  will be provided  free-of-charge.  
6.3.5  On Study  Visits  
Screening and Randomization (~1.5  hours):  
 
• Informed Consen t & Informed Consent  Quiz 
• Baseline assessments:  
o Drug and alcohol use history  (ASI-Lite) 
o Pre-arrest recall of drug and alcohol use (Timeline  Followback)  
o Prior Medication Treatment for Opioid Use Disorder exposure & preferences 
(MOUD Preference form)  
o Jail Electronic Medical Record medical and psychiatric history &  laboratory  
data, including HIV and HCV  status  
• Randomization envelope opened & completed by study staff and  participant  
o Medication dispensed (XRB or  SLB)  
o Additional  in-jail injections  of XRB may occur  if participant  is incarcerated  for 
over 4  weeks.  
Follow -Up Visits (v1 -4, ~1  hour)  
 
• Administrative data for SLB medication refills and post -release XRB  injections  
• Self-reported opioid and other drug use (Timeline  Followback)  
• Urine specimen collection and toxicology  testing  
• Adverse Event and Serious Adverse Event monitoring  (SAFTEE)  
• NYS Prescription Monitoring Data for community SLB pharmacy refill  reporting  
o I-STOP/PMP Registry  
• Treatment Retention Form completed  
• At visit 1 week 1, open -ended interview will be  administered.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
29  • At visit 3 week 4, second XRB administered, depending on prior injection  date.  
• At visit 3 week 4, pregnancy test will be administered..  
Research Visit 5 Week 8 (Final Visit, ~1  hour):  
 
• Medication is not  dispensed  
• For participants electing to continue in the 24 week extension, initial and/or additional 
XRB injection could be administered at this time point  
• Self-reported opioid and other drug use (Timeline  Followback)  
• Urine specimen collection and toxicology  testing  
• Pregnancy testing  
• Treatment Retention completed  
• Treatment Satisfaction completed  
• Adverse Event and Serious Adverse Event monitoring  (SAFTEE)  
 
• NYS Prescription Monitoring Data for commun ity SLB pharmacy refill  reporting  
o I-STOP/PMP Registry  
• Open -ended interview with participants concerning XRB vs. SLB  treatment  
satisfaction and  ease -of-use 
Treatment Visit 6 -10 Week 12,16, 20, 24, 28 (~1  hour):  
• 24 Week Extension Participants Only:  
o Self-reported opioid and other drug use (Timeline Followback)  
o Urine specimen collection and toxicology testing  
o Adverse Event and Serious Adverse Event monitoring (SAFTEE)  
o XRB administered, depending on prior injection date.  
o At visit 7 week 16  and visit 10 week 28 , pregnancy test will be 
administered  
o Qualitative Interviews (randomized to XRB treatment arm only) will 
be conducted at XRB injection treatment visits depending on 
participants’ medication schedules.  
Safety  Visit 11 Week 32 (~1  hour, final visit):  
o Self-reported opioid and other drug use (Timeline Followback)  
o Adverse Event and Serious Adverse Event monitoring (SAFTEE)  
o Qualitative Interviews if applicable  
o Treatment Satisfaction form  
In-Jail Feasibility:  
 
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
30  • Assessments of XRB vs. SLB  
o Logging the % eligible enrolling in the  study  
o The density of medical/nursing/pharmacy visits per arm and per  participant  
o Rates of medication  diversion.  
6.3.6  End of Study and  Follow -up 
After completion of the final visit (Visit 5, Week 8), study participation is complete for all 
participants who do not elect to continue and/or initiate treatment in the 24 week 
therapeutic extension of XRB treatment.  All participants will be provided information on XRB 
and SLB and will be encouraged  to continue treatment with the c ommunity opioid treatment 
provider of their choice.  All participants  will have  the option  of accessing  services  at 
Bellevue,  including  buprenorphine  and methadone maintenance treatment. It is likely that 
the majority of participants in  both arms will conti nue on SLB maintenance with the BHC 
Addiction Medicine clinic. XRB  may become a usual care option at BHC during the course 
of this trial, depending on  NYS Medicaid policies and H+H formulary  updates.  
For participants who continue in the 24 week therapeutic  extension, after completion of the 
final safety visit (Visit 11, Week 32), study participation is complete. All participants will be 
provided the same information as highlighted above. It is likely that the majority of 
participants in  this arm will continue on SLB maintenance with the BHC Addiction Medicine 
clinic.  
In-jail feasibility will be assessed during and post study completion as the data is  made 
available.  All adverse  event  and serious  adverse  event  monitoring  (SAFTEE)  will take place  
through out the study  and will be documented/reported  as necessary.  
6.3.7  Removal of  subjects  
Participation  in this pilot,  proof -of-concept,  RCT is entirely  voluntary  and participants  are free 
to withdraw at any time. In the event of early study termination, study staff will complete  the 
study termination form, modeled from a CRF of the parent XOR study. Any  participant  
withdrawing from the study prior to full study completion, regardless of study group, stands  a 
risk of relapsing to illicit opioid or other drug/alc ohol misuse. The study will assist  with 
treatment referrals for detox services at Bellevue Hospital Center, but will not  otherwise  
directly provide such services or medications. Otherwise any XRB or SLB patient who  has 
relapsed and is not interested in con tinuing their baseline study condition (i.e., an  XRB 
participant does not wish to continue injections due to side effects or for any other  reason) 
will be encouraged to pursue other appropriate community treatment, the menu of  which  
includes the robust add iction service offerings at Bellevue Hospital Center (BHC).  BHC's  
services are available to all persons, regardless of insurance status or an ability to pay,  and 
include emergency detox inpatient services, methadone treatment,  office -based  
buprenorphine, a nd intensive outpatient and dual diagnosis programs. These services  will 
consist of usual care occurring outside of the study and will not be directly provided by  or 
paid for by the  study.  
6.4.1  Statistical  Design  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
31   
 
This pilot study is exploratory, and Aim 1 is a qualitative estimation of the feasibility  and 
acceptability of this new form of buprenorphine in a large urban jail setting.  The study  will  
be moderately well -powered using a superiority contrast (A>>B) of XRB vs.  SLB 
surround ing Aim 2, retention in treatment post -release. Current rates of successful  retention 
in community buprenorphine treatment immediately at one month post -release are 30%  or 
lower (6). This current administrative data reflects closely results seen in an orig inal BUP  vs. 
methadone NYC jail RCT conducted in 2006 -2008 (7). If XRB retention at one month  post- 
release (Week 4) is 70% or greater, the study would be powered to detect a  significant 
difference  between  arms.  Analysis  of treatment  retention  among  XRB vs. SLB will consist  of 
simple 2x2 tables for counts and proportions of weeks retained in treatment by arm. We  are 
unlikely to extensively model and control for confounders or interaction  terms.  
6.4.2  Sample Size Considerations  
A total sample size of N=50 would allow for an estimate of an Odds Ratio of 2.0 -3.0 for  the 
rate of persons successfully in community buprenorphine treatment at 4 weeks  post-release  
(71% vs. 30% success favoring XRB; two -sided alpha of 0.05; 80+% power). The  proposed  
sample  size will not provide  a definitive  test of intervention  efficacy,  but is sized  for feasibility  
testing.  
6.4.3  Handling of Missing  Data  
Follow -up among individual participants at Bellevue Hospital is encouraged with  XOR's  
monetary incentives and tracking protocols. Partic ipants in either arm  choosing 
buprenorphine  f/u at Bellevue  will be particularly  likely  to complete  follow -up. Administrative  
and program data covering community pharmacy fills of buprenorphine products  and 
community provider reporting will be used to supplement treatment retention outcomes  (Aim 
2). Missing opioid urine toxicology data is considered  MissingAsPositive.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
32   
 
7 - Trial  Administration  
7.1 Ethical Considerations  
Federal Research among Prisoners . See section  5.3.2.  
Emotional Discomfo rt: There is a small chance that participants may become upset  when  
discussing their history of addiction problems, criminal justice involvement, family  conflict, 
prior trauma, or role failure, etc. We will discontinue administration of research  instrument s 
if a subject shows great discomfort or asks to terminate an interview. Such events have  not 
been observed in our preliminary  studies.  
7.2 Institutional Review Board (IRB)  Review  
The protocol, informed consent form(s), recruitment materials, and all participant  materials 
will be submitted to the appropriate IRB and institutional research committees for review  and 
approval. Approval of both the protocol and the consent form must be obtained before  any 
participant is enrolled. Any amendment to the proto col will require review and approval  by 
the IRB before the changes are implemented to the study. All changes to the consent  form 
will be IRB approved; a determination will be made regarding whether previously  consented 
participants need to be  re-consented.  
7.3 Subject Confidentiality  
Participants  will be asked  to provide  information  regarding  a number  of sensitive  behaviors  
(e.g.,  alcohol  and drug use, sexual  history,  criminal  history  and on-going  illicit activities).  
This type of personal  information  divulged  by participants  at study  visits  may have  adverse  
social and other unknown consequences for participants if released.  Therefore, in  addition  
to the safeguards put in place for the collection and storage of all data as described  above  
(section 11.0 Data Collection and Management), the study team obtained a  Federal  
Certificate  of Confidentiality  (COC  #DA-13-154) to encompass  protocol  activity  and further  
safeguard the possible risk of released confidential information. We will provide all  staff with 
training in their responsibilities for maintaining subject confidentiality; we will use  unique  
identifiers  to identify  subjects  in the database;  all data will be kept in locked  filing cabinets  or 
on our secure server to which only the investigators and project manager will have  access  
to. Study findings will utilize only aggregate data and no publication or presentation  will 
involve any use of individual  information.  
New York City's  H+HC's  Human  Subject's  Research  Protections  Programs  Policies  and 
Procedures procedure #26.3  states:  
If a patient is taking part in a Research Project involving a drug, device, or  procedure  
(therapeutic  trial),  the patient's  participation  must  be clearly  noted  in the patient's  electronic  
medical record. Researchers should scan and upload Informed Consent forms into  the 
electronic  medical  record  when  and where  possible,  preferably  to a research  folder.  
Research Records related to an FDA application must be maintained in accordance  with 
FDA requirem ents.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
33   
 
Therefore, if you are randomized to XRB: Information about your participation in this  study 
will be entered into your Electronic Medical Record (EMR). Once placed in your EMR,  the 
information will be available to all of your providers who participate in the EMR system  at 
NYC Health + Hospitals including those at Bellevue Medical Records office (HIM).  The 
purpose  of this entry  is to provide  research  information  that has the potential  to negatively  
impact your medical care. Bell evue HIM will scan and upload your informed consent to  your 
EMR, and are bound by the rules of confidentiality not to reveal your identity to  others.  
7.4 Deviations/Unanticipated  Problems  
Protocol  Deviations:  A protocol  deviation  is any noncompliance  with the clinical  trial protocol,  
GCP, or Manual of Procedures (MOP) requirements. The noncompliance may be either  on 
the part of the participant, the investigator, or the study site staff. As a result of  deviations,  
corrective  actions  are to be developed  by the site and implemented  promptly.  
These practices are consistent with ICH  E6: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and  4.5.3  
• 5.1 Quality Assurance and Quality Control, section  5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and  5.20.2.  
It is the responsibility of the site PI/study staff to use continuous vigilance to identify  and 
report  deviations  within  30 working  days  of identification  of the protocol  deviation,  or within  
30working days of the scheduled protocol -required  activity.  
Protocol  deviations  must  be reported  to the local IRB per their guidelines.  The site PI/study  
staff is responsible for knowing and adhering to their IRB requirements. Further  details  
about  the handling  of protocol  deviations  will be included  in the MOP.  
Unanticipated  Problems:  Incidents  or events  that meet  the OHRP  criteria  for UPs require  the 
creation and completion of an UP report form. It is the site investigator's responsibility  to 
report UPs to their IRB and to the DCC/study sponsor. The UP report will include  the 
following  information:  
• Protocol  identifying  information:  protocol  title and number,  PI's name,  and the IRB 
project  number;  
• A detailed description of the event, incident, experience, or  outcome;  
• An explanation  of the basis  for determining  that the event,  incident,  experience,  or 
outcome represents an  UP; 
• A description of any changes to the protocol or other corrective actions that  have  
been taken or are proposed in response to the  UP. 
To satisfy the requirement for prompt report ing, UPs will be reported using the  following  
timeline:  
UPs that are SAEs will be reported to the IRB and to the DCC/study sponsor within 30  days  
of the investigator  becoming  aware  of the event.  Any other  UP will be reported  to the IRB 
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
34   
 
and to the DCC/study sponsor within 30 days of the investigator becoming aware of  the 
problem.  All UPs should  be reported  to appropriate  institutional  officials  (as required  by an 
institution's written reporting procedures), the supporting agency head (or designee),  and 
OHRP  within  30 days  of the IR's receipt  of the report  of the problem  from the investigator.  
7.5 Data Quality Assurance  
Study clinicians and research staff will undergo t he same baseline training at the  inception  
of the study. The Program/Project Manager and Data Management staff will ensure  the 
quality of the clinicians' and the research assistants' administration of study  assessments  
and instruments  and of integrity  of the data recorded  through  regular  reviews  and on-going  
data monitoring.  
7.5.1  Data  Collection  
Electronic case report forms (CRFs) will be used to manage the data for this study, and  the 
Project Manager will work with study personnel to ensure the completeness and integrity  of 
all study data. These electronic CRFs will be taken from the parent XOR U01 NIDA  study. 
All data will be checked in real time, stored in a centralized database, reviewed  and 
monitored for completeness and accuracy, and undergo  a final cleaning following the  last 
subject visit, following which the study database will be locked. REDCap will be the  data 
entry and database platform for this  study.  
Protected Health Information (PHI) will be collected and stored in the form of  each  
participant's original signed informed consent and locator form.  These written  documents  
will be filed as individual  charts  and locked  securely  in a private  Department  of Population  
Health  office  cabinet.  These  charts  will be accessed  to call and follow -up with patients  post- 
release and to maintain the ICF on file. Participants will be assigned sequentially  numbered  
unique study ID numbers at the time of consent (e.g. #001 -50). These ID numbers will  be 
the only identifier entered on Case Report Fo rms (CRF) and research assessments  to 
distinguish one participant from another. Secure laptops will be used for web -based  data 
entry, CRF variables will be input into a secure central database on an NYULMC  server.  
The laptops  themselves  will be password -protected,  but will not store  PHI, study  ID number  
information or any research assessment data and will be used for web -based data  entry  
only. To maintain a link between the study ID and PHI for purposes of follow -up and  record - 
keeping, individual participant charts and research assessment/CRF data there will be  a 
master participant ID key that will contain each participant's PHI (name, DOB) and  their 
corresponding unique study ID number. This master key identifier file (.xls) will  be 
maintained by the PI and Project Manager on a secure NYULMC desktop file  and 
accessible only to study  staff.  
At the end of a three -year period following study closure, written identifiable data will  be 
destroyed.  De-identified  study  data will remain  in digital  and written file storage  for a period  
of 6 years following study conclusion and protocol close per standard NYU IRB  guidelines.  
The final de -identifiable digital dataset may be used by the Principal Investigator or  Co- 
Investigator  for secondary  analysis,  in which  case  future  IRB-approval  would  be sought.  
7.5.1.1  Access to  Source  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
35   
 
Source Documents  (PHI):  
 
• Original signed informed consent and consent form  quiz 
• Participant locator  form 
• Randomization  Form  
• Consent for the release of confidential alcohol or drug treatment information  
• Consent for the audio recording of in depth qualitative interviews  
These source documents containing PHI will be filed as individual charts and  locked  
securely  in a private  Depa rtment  of Population  Health  office  cabinet.  These  charts  will be 
accessed  to call and follow -up with patients  post-release  and to maintain  the ICF on file. 
Source Documents (Case Report Forms,  De-Identified):  
 
• ASILite: Baseline and  Follow -up 
• Demographics:  Baseline  
• Pre-arrest recall of drug and alcohol use (Timeline  Followback)  
• Self-report drug and alcohol use, post -release (Timeline  Followback)  
• Medication Treatment for Opioid Use Disorder exposure/preference (MOUD 
Preference)  
• Treatment Retention Form  
• Open -Ended Interview  Form  
• Qualitative Interview Form  
• Medical and Psychiatric History & Laboratory data (pulled from  EMR)  
• NYS Prescription Monitoring Form  
• New Arrests & New Incarceration Form  
• Inmate Lookup Form  
• Urine Toxicology Report  
• Pregnancy Testing  
• Adverse Event and Serious Adverse Event reporting  
Participants will be assigned sequentially numbered unique study ID numbers at the time  of 
consent  (e.g. #001 -50). These  ID numbers  will be the only identifier  entered  on Case  Report  
Forms  (CRF)  and research  assessments  to distinguish  one participant  from another.  Secure  
laptops will be used for web -based data entry, CRF variables will be input into a  secure 
central database on an NYULMC server. The laptops themselves wi ll be password - 
protected, but will not store PHI, study ID number information or any research  assessment  
data and will be used for web -based data entry only.  To maintain a link between the  study 
ID and PHI for purposes of follow -up and record -keeping, in dividual participant charts  and 
research assessment/CRF data there will be a master participant ID key that will  contain 
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
36  each participant's PHI (name, DOB) and their corresponding unique study ID number.  This 
master key identifier file (.xls) will be maint ained by the PI and Project Manager on a  secure 
NYULMC desktop file and accessible only to study  staff.  
7.5.1.2  Data  Storage/Security  
Data  will be collected  on both hard-copy  paper  CRFs  and electronic  CRFs.  Protected  Health  
Information  (PHI)  will be collected  and stored  in the form of each  participant's  original  signed 
informed consent, informed consent quiz, randomization form, and locator form.  These  
written  documents  will be filed as individual  charts  and locked  securely  in a private 
Department of Population Health office cabinet. These charts will be accessed to call  and 
follow -up with patients post -release and to maintain the ICF on file. Participants will  be 
assigned sequentially numbered unique study ID numbers at the time of consent (e.g.  #001 - 
50). These  ID numbers  will be the only identifier  entered  on Case  Report  Forms  (CRF)  and 
research assessments to distinguish one participant from another. Secure laptops will  be 
used for web -based data entry, CRF variables will be input into a secure  central  database  
on an NYULMC server. The laptops themselves will be password -protected, but will  not 
store PHI, study ID number information or any research assessment data and will be  used  
for web -based data entry only.  To maintain a link between the st udy ID and PHI  for 
purposes of follow -up and record -keeping, individual participant charts and  research 
assessment/CRF data there will be a master participant ID key that will contain  each  
participant's PHI (name, DOB) and their corresponding unique study ID number.  This  
master key identifier file (.xls) will be maintained by the PI and Project Manager on a  secure 
NYULMC desktop file and accessible only to study staff. All hard copy CRFs labeled  only 
with ID numbers will be filed in subject files, numbered sequentially. These subject files  will 
be kept in a securely locked, private Department of Population Health office  cabinet, 
separate from the individual locator  charts.  
7.6 Study  Records  
Study Records will  include:  
• All regulatory documents, kept up -to-date in regulatory binders and online  Research  
Navigator  
• All IRB approved protocol  versions  
• All IRB approved informed consent  forms  
• All IRB approved case report forms including  surveys  
• Individual participant charts  
• Original signed ICF & ICF  quiz 
• Randomization  form 
• Locator  Form  
• Medication  information  
• Subject ID File  
• All completed CRFs & surveys, organized by treatment  visit. 
7.6.1 Retention of  Records  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
37  At the end of a three -year period following study closure, written identifiable data will  be 
destroyed.  De-identified  study  data will remain  in digital  and written  file storage  for a period  
of 6 years following study conclusion and protocol close per standard NYU IRB  guidelines.  
The final de -identifiable digital dataset may be used by the Principa l Investigator or  Co- 
Investigator  for secondary  analysis,  in which  case  future  IRB-approval  would  be sought.  
 
7.7 Study  Monitoring  
The PI, Project/Program Manager, and study staff will work to ensure that all  information  
collected  is accurate  and properly  protected/secured.  The Principal  Investigator,  Dr. Joshua  
D. Lee, will assume responsibility for monitoring of data collection and of participant  safety. 
Any serious or unexpected adverse event will be reported immediately to: 1) the  NYC  
DOHMH and  NYUSOM -IRBs.  
7.8 Data Safety Monitoring  Plan  
A DSMB will monitor this trial. Dr. Rotrosen (NYU Psychiatry) will chair the DSMB.  Two 
other board members are to be determined.  The DSMB will conduct ongoing  protocol  
review, including data, protocol compliance, safety and efficacy data, in compliance  with 
NIDA and NYU IRB guidelines. All board members will meet NIDA requirements  regarding 
background  and experience,  and none  will have  ethical  conflicts,  including  financial  interest  
related  to study  outcome.  Individuals  invited  to serve  on the board  will disclose  any potential  
conflicts in writing. The board will meet every six months (unless more frequent  meetings  
are deemed  necessary.  Dr. Lee and other  research  personnel  will open  each  meetin g with a 
report on the trial's status, followed by a closed session under the direction of the  DSMB  
chairperson, during which time the investigators and research team may be present.  This  
will be followed by an executive session restricted to DSMB members. Issues related  to 
subject safety, conflict of interest, confidentiality, and ongoing study review (including  AEs,  
SAEs, and regulatory issues) will be assessed. Following each DSM Board  meeting, 
recommendations will be made to Dr. Lee, and a final  report (edited by all Board  members) 
will be prepared for reporting to NIDA, the DOHMH and NYU IRBs. The Data  Safety  
Monitoring Plan (DSMP) includes stopping rules that specify the outcome  differences  
detected  between  groups  during  an interim  analysis  that can result  in stopping  the pilot trial. 
In general, stopping rules will reflect one of the following conditions: 1) there is  clear 
evidence of harm or harmful side -effects of the treatment; 2) there is not likelihood  of 
demonstrating treatment benefit; 3 ) there is overwhelming evidence of the benefit of  the 
treatment. However because we are comparing alternative paradigms involving a  study 
medication (XRB) or community treatment as usual (SLB) that are already FDA -approved  as 
opioid treatment and do not suggest significant safety considerations, early stopping on  the 
basis of clear benefit (yes/no) is not anticipated in this  trial. 
7.9 Study  Modification  
Study  modifications,  such  as the addition  of new study  personnel,  may occur  throughout  this 
pilot stud y. All modifications will be submitted to the NYU IRB for review. All IRB  approved  
modifications will be stored in regulatory binders. If the IRB determines changes to  the 
protocol must be made, the protocol will be edited, submitted for NYU IRB review, an d all 
updated versions will then be implemented going  forward.  
7.10 Study  Discontinuation  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
38  There is very little chance that this pilot will be discontinued as both  investigational  
medications have been FDA approved and have been shown to be safe &  effective.  
Additionally,  this pilot,  proof -of-concept,  RCT has been  approved  by NIDA  for the period  of 1 
year only.  Study  termination  may be possible  in the event  of overwhelmingly  significant 
efficacy  differences  between  groups  or unacceptable  adverse  events.  
7.11 Study  Completion  
The study has an estimated completion date of June 29,  2019.  
7.12 Conflict of Interest Policy  
The independence of this pilot from any actual or perceived influence, such as by  the 
pharmaceutical  industry,  is critical.  Therefore  any actual  conflict  of interest  of persons  who 
have a role in the design, conduct, analysis, publication, or any aspect of this trial will  be 
disclosed  and managed.  Furthermore,  persons  who have  a perceived  conflict  of interest  will 
be required to have such conflicts  managed in a way that is appropriate to their  participation  
in the trial. The study leadership in conjunction with the NYU IRB has established  policies  
and procedures for all study group members to disclose all conflicts of interest and  will 
establish a m echanism for the management of all reported dualities of  interest.  
Any investigator who has a conflict of interest with this study (patent ownership, royalties,  or 
financial gain greater than the minimum allowable by their institution, etc.) must have  the 
conflict reviewed by the NYU Langone Conflict of Interest Management Unit (CIMU) with  a 
Committee -sanctioned conflict management plan that has been reviewed and approved  by 
the study  sponsor  prior to participation  in this study.  All NYULMC  investigators  will follow  the 
applicable conflict of interest  policies.  
7.13 Funding Source  
This pilot is supported  by a NIDA  Administrative  Supplement  as part of the on-going  XOR  
U01 award.  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
39   
 
Appendices  
 
 
Appendix  
#  
Name   
Title  
Section   
Topic  
 
1  
demographics_somatics_xor_nyu_v4.0.pdf    
6 
Methods   
6.2.1  
Efficacy  
 
2  
addiction_severity_index - 
lite_baseline_8.07.2014.pdf    
6 
Methods   
6.2.1  
Efficacy  
 
3  
addiction_severity_index - 
lite_drug_history_8.01.2014.pdf    
6 
Methods   
6.2.1  
Efficacy  
 
4  
addiction_severity_index -lite_follow - 
up_7.25.2014.pdf    
6 
Methods   
6.2.1  
Efficacy  
 
5  
tlfb_pre -arrest_calendar.pdf    
6 
Methods   
6.2.1  
Efficacy  
 
6  
tlfb_somatics_xor_nyu_v2_0.pdf    
6 
Methods   
6.2.1  
Efficacy  
 
7  
urine_toxicology_nyu_xor_v2.0.pdf    
6 
Methods   
6.2.1  
Efficacy  
 
 
 
8  
 
 
adverse_event_somatics_xor_nyu_v2.0.pdf    
 
6 
Methods   
6.2.2.1  AE 
Definition  
and 
Reporting  
 
 
 
9  
 
 
sae_xor_nyu_v_1.0.pdf    
 
6 
Methods   
6.2.2.1  AE 
Definition  
and 
Reporting  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
40   
 
List of  Tables  
 
 
Title 
 
Study Visit  Schedule  
 
Study  Flowchart  
Study Numbe r s18 -00823  December 11 , 2019 Version 10  
41   
 
References  
1. The National  Alliance  of Advocates  for Buprenorphine  Treatment.  What  exactly  is Buprenorphine  
(2018, June 12); Retrieved from:  https://www.naabt.org/faq_answers.cfm?ID=2 . 
2. Indivior. FDA Approves SUBLOCADETM (Buprenorphine Extended -Release), the First and  Only 
Once -Monthly Injectable Buprenorphine Formulation to Treat Moderate  to Severe Opioid  Use 
Disorder.  2017;  
3. CDC. Drug Overdose Death Data.  2017;  
4. CDC. Wide -ranging online data for epidemiologic research (WONDER).  2017;  
5. Alex B, Weiss  DB, Kaba  F, Rosner  Z, Lee D, Lim S, Venters  H, MacDonald  R. Death  After  Jail 
Release. Jan 2017;  23(1):83 -87. 
6. Giftos, J. Personal Communication, 2/1/2018. Medical Director, Opioid Treatment  Program.  
7. Magura S, Lee JD, Hershberger J, Joseph H, Marsch L, Shropshire C, Rosenblum  A. 
Buprenorphine and methadone maintenance in jail and post -release: a randomized clinical trial.  Jan 
1, 2009;  99(1-3):222 -230. 
8. Lee JD, Grossman  E, Truncali  A, Rotrosen  J, Rosenblum  A, Magura  S, Gourevitch  MN. 
Buprenorphine -naloxone maintenance following release from jail. 2012;  33(1):40 -47. 
9. Brinkley -Rubinstein L, Zaller N, Martino S, Cloud DH, McCauley E, Heise A, Seal D.  Criminal  
justice  continuum  for opioid  users  at risk of overdose.  Feb 24, 2018;  doi: S0306 -4603(18)30089 -3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  